The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| MPLT | N/A | N/A | N/A | -30% |
| S&P | +12.94% | +86.25% | +13.25% | -1% |
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for brain disorders. It develops the ML-007-MA product for treatment of schizophrenia and ADP. Its platforms include Optogenetics, Transcriptnomics, and STARmap. The company was founded by Christopher A. Kroeger, Karl Deisseroth, Robert Malenka, and Karoly Nikolich in November 2018 and is headquartered in Redwood City, CA.
No news articles found for MapLight Therapeutics.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.14M | 21.4% |
| Employees | 109 | 0.0% |
| Net Income | -$29.85M | -62.2% |
| EBITDA | -$30.53M | -54.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $33.47M | 0.0% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $5.37M | 0.0% |
| Short Term Debt | $0.83M | 0.0% |
No data available for this period.
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$34.03M | -91.0% |
| Operating Free Cash Flow | -$33.97M | -93.7% |
| Metric | Q1 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|
| Total Debt | $5.81M | $6.40M | $6.21M | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
